BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) and Shilpa Medicare Limited (“Shilpa ...
Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma. The Food and Drug Administration (FDA) has approved ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) along with Shilpa Medicare Limited, Thursday announced that the U.S. Food and Drug Administration has approved BORUZU, the first ready-to-use version of ...
Co reported on the presentation of results from four clinical trials of Velcade based therapies that showed consistently high survival and complete remission / complete response rates in newly ...
Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces the ...
Co reported on the presentation of results from clinical trials of Velcade based therapies that showed high complete remission / complete response rates in previously treated multiple myeloma patients ...
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of BORUZU™, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback